ArticleInfection and drug resistance2025
Invasive Mucormycosis in a Chronic Lymphocytic Leukemia Patient on Zanubrutinib: A Case Report.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive mucormycosis is a severe fungal infection that predominantly affects immunocompromised and diabetic patients. This case study highlights the importance of early diagnosis and pathogen-specific antifungal therapy in managing invasive mucormycosis among high-risk patients. Case Description: A 47-year-old male with chronic lymphocytic leukemia (Rai stage IV) on zanubrutinib and with uncontrolled diabetes was admitted to Jiangxi Cancer Hospital on November 7, 2021. Imaging revealed pulmonary infection and splenic infarction, while laboratory findings suggested disseminated intravascular coagulation. Despite empirical broad-spectrum antibiotics, his condition worsened, necessitating an emergency splenectomy. Postoperatively, fluconazole was added to his antimicrobial regimen, but he developed respiratory failure, liver and renal dysfunction, and persistent hyperglycemia. A bronchial alveolar lavage sample was sent for metagenomic next-generation sequencing (mNGS) to identify the pathogen. Despite intensive care, he deteriorated rapidly, developing myocardial injury, metabolic acidosis, and multiorgan failure, leading to death on November 13, 2021. mNGS results, received after the patient's death, identified Conclusion: This study presents a case of rapidly progressive mucormycosis co-infected with bacterial and viral pathogens, highlighting the importance of early intervention and accurate diagnosis. Delayed identification of the fungal pathogen significantly hindered timely antifungal intervention, underscoring the importance of appropriate empirical therapies in hematological patients treated with zanubrutinib. Future research should focus on antifungal stewardship and epidemiological surveillance studies to improve early detection and guide targeted empirical treatment for high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.